Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016 (2016), Article ID 4158287, 13 pages
http://dx.doi.org/10.1155/2016/4158287
Research Article

Role of Transforming Growth Factor-β1 and Smads Signaling Pathway in Intrauterine Adhesion

1Department of Gynecology, Third Xiangya Hospital of Central South University, 138 Tongzipo Road, Changsha, Hunan 410013, China
2Department of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan, China
3Department of OB/GYN, Baylor College of Medicine, 6651 Main Street, 10th Floor, Houston, TX 77030, USA
4Center for Medical Experiments, Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Received 8 November 2015; Revised 19 January 2016; Accepted 26 January 2016

Academic Editor: Marc Pouliot

Copyright © 2016 Umme Salma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Baakdah and T. Tulandi, “Adhesion in gynecology complication, cost, and prevention: a review,” Surgical technology international, vol. 14, pp. 185–190, 2005. View at Google Scholar · View at Scopus
  2. H. Fritsch, “Ein Fall von volligen Schwund der Gebaumutterhohle nach Auskratzung,” Zentralblatt für Gynäkologie, vol. 18, pp. 1337–1342, 1894. View at Google Scholar
  3. M. P. Diamond and M. L. Freeman, “Clinical implications of postsurgical adhesions,” Human Reproduction Update, vol. 7, no. 6, pp. 567–576, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Ellis, “The causes and prevention of intestinal adhesions,” British Journal of Surgery, vol. 69, no. 5, pp. 241–243, 1982. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Eckes, P. Zigrino, D. Kessler et al., “Fibroblast-matrix interactions in wound healing and fibrosis,” Matrix Biology, vol. 19, no. 4, pp. 325–332, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Gabbiani, “The myofibroblast in wound healing and fibrocontractive diseases,” The Journal of Pathology, vol. 200, no. 4, pp. 500–503, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. A. B. Roberts and M. B. Sporn, “Transforming growth factor-b,” in The Molecular and Cellular Biology of Wound Repair, pp. 275–308, Springer, Berlin, Germany, 1996. View at Google Scholar
  8. T. Nakamura, R. Sakata, T. Ueno, M. Sata, and H. Ueno, “Inhibition of transforming growth factor β prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine- treated rats,” Hepatology, vol. 32, no. 2, pp. 247–255, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. J. B. Kopp, V. M. Factor, M. Mozes et al., “Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease,” Laboratory Investigation, vol. 74, no. 6, pp. 991–1003, 1996. View at Google Scholar · View at Scopus
  10. S. N. Giri, D. M. Hyde, and M. A. Hollinger, “Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice,” Thorax, vol. 48, no. 10, pp. 959–966, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. T. J. Broekelmann, A. H. Limper, T. V. Colby, and J. A. Mcdonald, “Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 15, pp. 6642–6646, 1991. View at Publisher · View at Google Scholar · View at Scopus
  12. J. P. Annes, J. S. Munger, and D. B. Rifkin, “Making sense of latent TGFβ activation,” Journal of Cell Science, vol. 116, no. 2, pp. 217–224, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Heydemann, E. Ceco, J. E. Lim et al., “Latent TGF-β-binding protein 4 modifies muscular dystrophy in mice,” The Journal of Clinical Investigation, vol. 119, no. 12, pp. 3703–3712, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Taipale, J. Saharinen, K. Hedman, and J. Keski-Oja, “Latent transforming growth factor-β1 and its binding protein are components of extracellular matrix microfibrils,” Journal of Histochemistry and Cytochemistry, vol. 44, no. 8, pp. 875–889, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. P. K. Mehta and K. K. Griendling, “Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system,” American Journal of Physiology, vol. 292, no. 1, pp. C82–C97, 2007. View at Google Scholar
  16. N. Chegini, Y. Zhao, R. S. Williams, and K. C. Flanders, “Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-β1 (TGF-β1), TGF-β2, TGF-β3, and TGF-β type II receptor messenger ribonucleic acid and protein and contains [125I]TGF-β1-binding sites,” Endocrinology, vol. 135, no. 1, pp. 439–449, 1994. View at Publisher · View at Google Scholar
  17. D. A. Lawrence, “Transforming growth factor-β: a general review,” European Cytokine Network, vol. 7, no. 3, pp. 363–374, 1996. View at Google Scholar · View at Scopus
  18. M. H. Branton and J. B. Kopp, “TGF-β and fibrosis,” Microbes and Infection, vol. 1, no. 15, pp. 1349–1365, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Casslén, T. Sandberg, B. Gustavsson, R. Willén, and M. Nilbert, “Transforming growth factor β1 in the human endometrium. Cyclic variation, increased expression by estradiol and progesterone, and regulation of plasminogen activators and plasminogen activator inhibitor-1,” Biology of Reproduction, vol. 58, no. 6, pp. 1343–1350, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Yamamoto, S. Takagawa, I. Katayama et al., “Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma,” Journal of Investigative Dermatology, vol. 112, no. 4, pp. 456–462, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Zhang, L. L. McCormick, and A. C. Gilliam, “Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma,” Journal of Investigative Dermatology, vol. 121, no. 4, pp. 713–719, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Verrecchia, M.-L. Chu, and A. Mauviel, “Identification of novel TGF-β/smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach,” The Journal of Biological Chemistry, vol. 276, no. 20, pp. 17058–17062, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Massagué and D. Wotton, “Transcriptional control by the TGF-β/Smad signaling system,” The EMBO Journal, vol. 19, no. 8, pp. 1745–1754, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Moustakas, S. Souchelnytskyi, and C.-H. Heldin, “Smad regulation in TGF-β signal transduction,” Journal of Cell Science, vol. 114, no. 24, pp. 4359–4369, 2001. View at Google Scholar · View at Scopus
  25. P. Kavsak, R. K. Rasmussen, C. G. Causing et al., “Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation,” Molecular Cell, vol. 6, no. 6, pp. 1365–1375, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Wang, X. R. Huang, A. G. Li et al., “Signaling mechanism of TGF-β1 in prevention of renal inflammation: role of Smad7,” Journal of the American Society of Nephrology, vol. 16, no. 5, pp. 1371–1383, 2005. View at Publisher · View at Google Scholar
  27. S. M. Ka, X. R. Huang, H. Y. Lan, P. Y. Tsai et al., “Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice,” Journal of the American Society of Nephrology, vol. 18, no. 6, pp. 1777–1788, 2007. View at Publisher · View at Google Scholar
  28. B. Wang, J. Hao, S. C. Jones, M.-S. Yee, J. C. Roth, and I. M. C. Dixon, “Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 282, no. 5, pp. H1685–H1696, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Li, X. Qu, J. Yao et al., “Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy,” Diabetes, vol. 59, no. 10, pp. 2612–2624, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Jinnin, H. Ihn, and K. Tamaki, “Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-β1-induced extracellular matrix expression,” Molecular Pharmacology, vol. 69, no. 2, pp. 597–607, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. P. D. Arkwright, V. Pravica, P. J. Geraghty et al., “End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 3, pp. 384–389, 2003. View at Publisher · View at Google Scholar
  32. P. D. Arkwright, S. Laurie, M. Super et al., “TGF-β1 genotype and accelerated decline in lung function of patients with cystic fibrosis,” Thorax, vol. 55, no. 6, pp. 459–462, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. E. P. Böttinger, “TGF-beta in renal injury and disease,” Seminars in Nephrology, vol. 27, no. 3, pp. 309–320, 2007. View at Google Scholar
  34. R. Derynck and Y. E. Zhang, “Smad-dependent and Smad-independent pathways in TGF-β family signalling,” Nature, vol. 425, no. 6958, pp. 577–584, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Savage, P. Das, A. L. Finelli et al., “Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor β pathway components,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 2, pp. 790–794, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. J. G. Schenker, “Etiology of and therapeutic approach to synechia uteri,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 65, no. 1, pp. 109–113, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Z. Polishuk, “Endometrial regeneration and adhesion formation,” South African Medical Journal, vol. 49, no. 12, pp. 440–442, 1975. View at Google Scholar · View at Scopus
  38. J. Hao, H. Ju, S. Zhao, A. Junaid, T. Scammell-La Fleur, and I. M. C. Dixon, “Elevation of expression of Smads 2, 3, and 4, decorin and TGF-β in the chronic phase of myocardial infarct scar healing,” Journal of Molecular and Cellular Cardiology, vol. 31, no. 3, pp. 667–678, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Hayashi, S. Abdollah, Y. Qiu et al., “The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling,” Cell, vol. 89, no. 7, pp. 1165–1173, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Takagawa, G. Lakos, Y. Mori, T. Yamamoto, K. Nishioka, and J. Varga, “Sustained activation of fibroblast transforming growth factor-β/Smad signaling in a murine model of scleroderma,” Journal of Investigative Dermatology, vol. 121, no. 1, pp. 41–50, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Afrakhte, A. Morén, S. Jossan et al., “Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members,” Biochemical and Biophysical Research Communications, vol. 249, no. 2, pp. 505–511, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. H.-J. Zhu, J. Iaria, and A. M. Sizeland, “Smad7 differentially regulates transforming growth factor β-mediated signaling pathways,” Journal of Biological Chemistry, vol. 274, no. 45, pp. 32258–32264, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Ebisawa, M. Fukuchi, G. Murakami et al., “Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation,” Journal of Biological Chemistry, vol. 276, no. 16, pp. 12477–12480, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Tan, W. He, X. Lin, L. P. Kiss, and Y. Liu, “Smad ubiquitination regulatory factor-2 in the fibrotic kidney: regulation, target specificity, and functional implication,” American Journal of Physiology—Renal Physiology, vol. 294, no. 5, pp. F1076–F1083, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Kawabata and K. Miyazono, “Signal transduction of the TGF-β superfamily by Smad proteins,” The Journal of Biochemistry, vol. 125, no. 1, pp. 9–16, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Massagué, “TGF-β signal transduction,” Annual Review of Biochemistry, vol. 67, no. 1, pp. 753–791, 1998. View at Publisher · View at Google Scholar
  47. C. Savage, P. Das, A. L. Finelli et al., “Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor beta pathway components,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 2, pp. 790–794, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. S.-J. Chen, W. Yuan, S. Lo, M. Trojanowska, and J. Varga, “Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta,” Journal of Cellular Physiology, vol. 183, no. 3, pp. 381–392, 2000. View at Google Scholar · View at Scopus
  49. L. Vindevoghel, R. J. Lechleider, A. Kon et al., “SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor beta,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 25, pp. 14769–14774, 1998. View at Publisher · View at Google Scholar
  50. K. C. Flanders, “Smad3 as a mediator of the fibrotic response,” International Journal of Experimental Pathology, vol. 85, no. 2, pp. 47–64, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Y. Lan, “Smad7 as a therapeutic agent for chronic kidney diseases,” Frontiers in Bioscience, vol. 13, no. 13, pp. 4984–4992, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Wang, A. Omar, T. Angelovska et al., “Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 293, no. 2, pp. H1282–H1290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. S.-J. Chen, W. Yuan, Y. Mori, A. Levenson, M. Trojanowska, and J. Varga, “Stimulation of type I collagen transcription in human skin fibroblasts by TGF-β: involvement of Smad 3,” Journal of Investigative Dermatology, vol. 112, no. 1, pp. 49–57, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. B. Hu, Z. Wu, and S. H. Phan, “Smad3 mediates transforming growth factor-β-induced α-smooth muscle actin expression,” American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 3, pp. 397–404, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. X.-M. Meng, Y. Zhang, X.-R. Huang et al., “Treatment of renal fibrosis by rebalancing TGF-β/Smad signaling with the combination of asiatic acid and naringenin,” Oncotarget, vol. 6, no. 35, pp. 36984–36997, 2015. View at Google Scholar